



City Research Online

City, University of London Institutional Repository

Citation: Barnicot, K. & Crawford, M. (2019). Dialectical behaviour therapy v. mentalisation-based therapy for borderline personality disorder. *Psychological Medicine*, 49(12), pp. 2060-2068. doi: 10.1017/S0033291718002878

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/24748/>

Link to published version: <https://doi.org/10.1017/S0033291718002878>

Copyright: City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

Reuse: Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

City Research Online:

<http://openaccess.city.ac.uk/>

publications@city.ac.uk

Dialectical behaviour therapy versus mentalization-based therapy for borderline personality disorder

Kirsten Barnicot,* PhD. Department of Medicine, Imperial College London. Address: Centre for Psychiatry, Imperial College London, Commonwealth Building, Du Cane Road, London, W12 0NN, United Kingdom.

Mike Crawford, MD, FRCPsych. Department of Medicine, Imperial College London. Address: Centre for Psychiatry, Imperial College London, Commonwealth Building, Du Cane Road, London, W12 0NN, United Kingdom.

* Corresponding author

Correspondence. Dr Kirsten Barnicot, Centre for Psychiatry, Imperial College London, Commonwealth Building, Du Cane Road, London, W12 0NN, United Kingdom. Email k.barnicot@imperial.ac.uk

Financial Support

The present study was funded by a Postdoctoral Research Fellowship awarded to KB from the United Kingdom National Institute for Health Research: PDF-2013-06-054.

Word count: 4199

Background. Dialectical behaviour therapy (DBT) and mentalization based therapy (MBT) are both widely used evidence-based treatments for borderline personality disorder (BPD), yet a head-to-head comparison of outcomes has never been conducted. The present study therefore aimed to compare the clinical outcomes of DBT versus MBT in patients with BPD.

Methods. A non-randomised comparison of clinical outcomes in N = 90 patients with BPD receiving either DBT or MBT over a 12-month period.

Results. After adjusting for potentially confounding differences between participants, participants receiving DBT reported a significantly steeper decline over time in incidents of self-harm (adjusted $IRR = 0.93$, 95% C.I. 0.87 to 0.99, $p = 0.02$) and in emotional dysregulation (adjusted $\beta = -1.94$, 95% C.I. -3.37 to -0.51, $p < 0.01$) than participants receiving MBT. Differences in treatment dropout and use of crisis services were no longer significant after adjusting for confounding, and there were no significant differences in BPD symptoms or interpersonal problems.

Conclusions. Within this sample of people using specialist personality disorder treatment services, reductions in self-harm and improvements in emotional regulation at 12 months were greater amongst those receiving DBT than amongst those receiving MBT. Experimental studies assessing outcomes beyond 12 months are needed to examine whether these findings represent differences in the clinical effectiveness of these therapies.

Borderline Personality Disorder (BPD) is a severe mental health problem that is associated with emotional dysregulation, extreme subjective distress, high levels of psychosocial and work impairment, and frequent use of A&E and inpatient services linked to self-harm and suicide attempts (Ansell *et al.* 2007). Dialectical behaviour therapy (DBT) and mentalization based therapy (MBT) were developed specifically for the treatment of BPD and an emerging evidence base for the effectiveness of each of those treatment modalities has been identified by meta-analyses and Cochrane reviews (Stoffers *et al.* 2012; Cristea *et al.* 2016). Both treatment models are increasingly widely available in the USA, Australasia, UK and Europe (University College London, 2014; Behavioral Tech, 2017; Dale *et al.* 2017). However, regional health localities commonly offer one or another, rather than both (Dale *et al.* 2017), and local treatment commissioners have little information to guide them as to which, if either, will be most effective for their patients. A head-to-head comparison of these two approaches has never been conducted, and indeed, few evaluations of either approach have compared outcomes with another specialised psychological treatment for BPD. DBT and MBT have each arisen from different traditions within psychotherapy and accordingly take differing approaches to the treatment of BPD, which in turn could render each differentially beneficial for different aspects of the BPD phenotype. DBT arose out of cognitive behavioural approaches but has been specifically tailored for BPD by incorporation of validation strategies, mindfulness and a focus on directly improving patients' emotion regulation skills through group-based behavioural skills training (Linehan, 1993a; Linehan, 1993b). By contrast, MBT arose out of the psychodynamic tradition, but has been specifically adapted for BPD by incorporation of an emphasis on fostering mentalization - the ability to reflect coherently on the mental states of oneself and of other people - in interpersonal contexts

(Bateman & Fonagy, 2006). A quasi-experimental comparison of the clinical outcomes of each approach may begin to yield insights on differential outcomes in a context that is representative of everyday clinical practice. The current study therefore aimed to address the following question: In patients with borderline personality disorder, do clinical outcomes at 12 months differ between patients receiving dialectical behaviour therapy and those receiving receive mentalization based therapy?

Methods

Design

A quasi-experimental non-randomised comparison of clinical outcomes in 90 patients receiving dialectical behaviour therapy (DBT) or mentalization based therapy (MBT) in specialist personality disorder services, with treatment type determined by local service availability based on patients' geographical location.

Inclusion and Exclusion Criteria

Participants were included if they:

- 1) Met criteria for DSM-IV borderline personality disorder
- 2) Were about to begin either outpatient DBT or MBT.

The exclusion criteria were intellectual disability or difficulty communicating in English of sufficient severity to prevent completion of study questionnaires, and/or insufficient capacity to provide informed consent for study participation.

Setting

Participants were recruited between March 2014 and September 2016 from six personality disorder services across five NHS Trusts in London and Southampton, in the United Kingdom. The treatment capacity of the participating services ranged from 6 to 20 patients at a time. The number of staff delivering treatment at each service ranged from 4 to 7, usually including some full and some part-time staff, and professional backgrounds included psychiatry, clinical psychology, social work, mental health nursing and psychotherapy. Three services provided DBT (12 month course) and three provided MBT (18 month course). All participants took part in the study only over a 12 month period in order to render clinical outcomes comparable between the two treatment modalities. The DBT services all provided weekly individual therapy and group skills training, telephone skills coaching and team consultation. The MBT services all provided weekly or fortnightly individual therapy and weekly group therapy. They also provided a short-term group programme which involves weekly groups delivered over a ten-week period, offering psychoeducation and support aimed at helping clients get a better understanding of their problems and suggestions for better ways of dealing with them. These groups serve a dual function of providing a brief intervention to all those who attend and giving clients and staff an opportunity to consider whether longer term group treatment may be of benefit. However, they are not part of the MBT intervention as manualised by Bateman and Fonagy (2006).

Procedure

At the beginning of their treatment, patients were given verbal information about the study by their DBT or MBT clinicians and asked for verbal consent to be contacted by the research team. A researcher then met with the participant to provide written information about the study and obtain written informed consent. After assessment of participants using the

Structured Clinical Interview for DSM-IV Axis II to confirm that they met criteria for borderline personality disorder (First *et al.* 1997), baseline measures were administered. Follow-up assessments were then conducted with participants at 3, 6, 9 and 12 months after the baseline assessment. Both patients completing treatment and patients dropping out of treatment were followed up. Participants received a £30 compensation for attending the baseline assessment, and a £15 compensation for each follow-up.

Baseline Measures

Personality disorder diagnosis. The Structured Clinical Interview for DSM- IV, Axis II (SCID-II) (First *et al.* 1997), was used at baseline to assess participants' DSM-IV Axis II personality disorder diagnoses. This semi-structured diagnostic interview demonstrates good inter-rater reliability (Maffei *et al.* 1997).

Axis I disorders. The Traumatic Antecedents Questionnaire self-report measure (Herman *et al.* 1989) was used at baseline to determine whether participants had experienced a Criterion A traumatic event, as defined by DSM-V (American Psychiatric Association, 2013). In participants for whom a history of Criterion A trauma was indicated, the PTSD module of the Structured Clinical Interview for DSM-IV-TR, Axis I (SCID-I) was administered (First *et al.* 2002). This semi-structured diagnostic interview demonstrates a good level of inter-rater reliability for assessment of PTSD (Skre *et al.* 1991, Zanarini *et al.* 2000). The Mini International Neuropsychiatric Interview (MINI) was administered at baseline to assess major depressive disorder, substance dependence, alcohol dependence and psychotic symptoms (Sheehan *et al.* 1998). This semi-structured diagnostic interview demonstrates good inter-rater and test–retest reliability and convergent validity (Sheehan *et al.* 1997).

Outcome measures

Treatment dropout or completion. Treatment completion was defined as completing at least 12 months of either treatment modality. Individuals completing less than 12 months of treatment were classed as treatment dropouts. Services offering DBT followed a protocol whereby all participants missing four or more consecutive group sessions or four or more consecutive individual sessions were asked to discontinue treatment, whilst services offering MBT held team discussions of cases of poor attendance and came to a consensus on whether to ask the patient to discontinue treatment.

Crisis service use. Participants were asked to recall any Accident and Emergency (A&E) and psychiatric hospital admissions in the 12 months prior to the baseline interview or in the 3 months between each follow-up.

Deliberate self-harm. The Suicide Attempt Self Injury Interview (SASII) was used to enumerate incidents of self-harm in the 3 and in the 12 months before beginning treatment, and in the 3 months between each follow-up (Linehan *et al.* 2006a). This semi-structured interview demonstrates good inter-rater reliability and adequate concurrent validity (Linehan *et al.* 2006a). Self-harm was operationalised as “Any overt, acute, nonfatal self-injurious act where both act and bodily harm or death are clearly intended (i.e., both the behavioral act and the injurious outcomes are not accidental) that results in actual tissue damage, illness, or, if no intervention from others, risk of death or serious injury” (Linehan 1996).

BPD symptom severity. The Borderline Evaluation of Severity over Time (BEST) (Pfohl *et al.* 2009), a 15-item self-report measure, was administered at baseline and at each 3-month follow-up. Each item is answered using a Likert scale from “Not at all” or “Almost never” (1) through to “Extremely” or “Almost always” (5). Possible scores range from 12 to 72, with

higher scores indicating more severe BPD symptoms. It demonstrates moderate test-retest reliability, high internal consistency and high discriminant validity (Pfohl *et al.* 2009).

Emotional dysregulation. The Difficulties in Emotion Regulation Scale (DERS) (Gratz & Roemer, 2004), a 36-item self-report measure, was administered at baseline and at each 3 month follow-up. Each item is answered using a Likert scale from “Almost never” (1) to “Almost always” (5), and possible scores range from 36 to 180, with higher scores indicating a greater degree of emotional dysregulation. The measure demonstrates high internal consistency, good test–retest reliability, and adequate construct and predictive validity (Gratz & Roemer, 2004).

Dissociation. The Dissociative Experiences Scale (Bernstein & Putnam, 1986), a 28-item self-report measure, was administered at baseline and at each 3-month follow-up. Each item is answered using a Likert scale indicating the percentage of the time that the participant experiences it, from 0% increasing in 10% increments to 100%. The mean score is used and thus possible scores range from 0 to 100. It demonstrates good test-retest reliability, split half reliability, internal consistency and convergent and predictive validity (Bernstein & Putnam, 1986; van Ijzendoorn & Schuengel, 1996).

Difficulties in interpersonal relationships. The Alterations in Relationships subscale of the Structured Interview for Disorders of Extreme Stress - Self-Report (SIDES-SR) was administered at baseline and at the 12-month follow-up (Pelcowitz *et al.* 1997; van der Kolk, 2002). The SIDES-SR is a 5-item self-report measure of different aspects of complex reactions to trauma, known as “disorders of extreme stress not otherwise specified”. Each item has 4 possible responses scored from 0 to 3, with response options personalised to each

question. The 5 items of the Alterations in Relationships subscale comprise difficulties in trusting others, avoidance in relationships, difficulties with conflict in relationships, repeatedly being hurt by others and repeatedly hurting others. The internal consistency (Cronbach's alpha) of these 5 items was 0.68 at baseline and 0.70 at month 12.

Analysis

All analyses were conducted using STATA/ SE version 14.2 (StataCorp, 2015). Analyses were conducted on an intention-to-treat basis whereby data from individuals who dropped out of treatment was retained in the models. Where the dependent variable was self-harm, participants with no history of self-harm in the 12 months prior to treatment were omitted from the analysis. Linear regression was used for continuous dependent variables, logistic regression for binary dependent variables, and negative binomial regression for overdispersed count dependent variables (i.e. number of incidents of self-harm). Where continuous dependent variables did not conform to a normal distribution, robust standard errors were calculated.

It was first established whether there was any difference at the start of the study between participants receiving DBT or to MBT, or between participants who went on to complete or to drop out of treatment, on key sociodemographic and mental health variables. Variables found to differentiate DBT and MBT patients, or treatment completers and dropouts, were considered as potential confounders in subsequent analyses. The effect of treatment type on treatment completion, and on clinical outcomes at month 12, was examined, and multilevel modelling was used to establish whether there was any difference between participants receiving DBT versus MBT in the trajectory of change between baseline and 12 months on any of the outcome variables. The multilevel models included a random effect to adjust for

clustering between repeated measures of variables over time within each participant. If significant treatment effects were found in initial “basic” models, an “adjusted” model was run, examining the simultaneous effect of the month 0 measurement of the outcome variable, time, treatment modality, treatment completion, the interaction of time and treatment modality, the interaction of time and treatment completion, and any other month 0 mental health measures that had been shown to differ between participants receiving DBT versus MBT, or between participants completing versus dropping out of treatment.

Results

Description of the sample

Recruitment into the research and follow-up rates are summarised in Figure 1. Of 98 eligible individuals approached to take part in the study, 90 consented (consent rate 92%). The sociodemographic and mental health characteristics of the sample at the start of the study are summarised in Table 1, which illustrates the high levels of self-harming behaviour, emotional dysregulation, dissociation and Axis 1 comorbidities, with post-traumatic stress disorder being particularly common.

[Insert Table 1 about here].

Differences between participants receiving DBT and those receiving MBT

Fifty-eight participants received DBT and thirty-two received MBT. Participants receiving DBT were more likely to have engaged in self-harm and/or to have attended A&E in the 12 months before treatment (Self-harm $OR = 7.84$, 95% C.I. 1.5 to 40.4, $p = 0.01$; A&E $OR =$

3.82, 95% C.I. 1.50 to 9.71, $p < 0.01$), more frequently had comorbid post-traumatic stress disorder ($OR = 3.73$, 95% C.I. 1.4 to 10.1, $p = 0.01$), and began treatment with significantly higher levels of emotional dysregulation ($\beta = 13.9$, 95% C.I. 1.3 to 26.6, $p = 0.03$). There was a trend for participants initiating MBT to be older than those initiating DBT ($\beta = -5.02$, 95% C.I. -10.65 to 0.61, $p < 0.10$). These baseline differences between participants were adjusted for in subsequent analyses of differential outcomes in DBT and MBT patients.

Differences between participants completing treatment and those dropping out

Forty-eight participants completed at least 12 months of treatment, and forty-two participants dropped out of treatment before completing 12 months. Participants who went on to complete at least 12 months of treatment were less likely to have met criteria for substance dependence ($OR = 0.36$, 95% C.I. 0.14 to 0.98, $p = 0.04$), and reported higher levels of dissociation at the start of treatment ($\beta = 11.5$, 95% C.I. 2.0 to 20.9, $p = 0.02$). There were non-statistically significant trends towards treatment completers being more likely to be female ($OR = 2.60$, 95% C.I. 0.99 to 6.77, $p = 0.05$) and less likely than dropouts to have had a psychiatric hospital admission in the 12 months before treatment ($OR = 0.46$, 95% C.I. 0.19 to 1.14, $p = 0.09$). These differences between participants were adjusted for in subsequent analyses of differential outcomes in DBT and MBT patients.

Treatment dropout from DBT and MBT

Patients receiving DBT were significantly less likely to complete at least 12 months of treatment than those receiving MBT (completion rate 42% versus 72%; $OR = 0.28$, 95% C.I. 0.11 to 0.72, $p < 0.01$). However, this difference was no longer significant after adjusting for

baseline differences between DBT and MBT participants, using multiple regression models in which participants' age, gender, baseline emotional dysregulation, dissociation, substance dependence and PTSD comorbidity, and history of self-harm, A&E admission or psychiatric hospitalisation in the 12 months before treatment were held constant (adjusted $OR = 0.23$, 95% C.I. 0.05 to 1.04, $p = 0.06$). Subsequent analyses of differential outcomes in DBT and MBT patients adjusted for whether or not a participant had completed treatment.

Differences between DBT and MBT on clinical outcome measures at month 12

Clinical outcomes in DBT and MBT patients twelve months after starting treatment are shown in Table 2. At the 12-month follow-up there were no differences between participants receiving DBT and those receiving MBT in number of incidents of self-harm, BPD severity, emotional dysregulation, relationships with others, or dissociation. Participants receiving DBT were more likely to be admitted to A&E ($OR = 3.65$, 95% C.I. 1.25 to 10.67, $p = 0.02$) and were more likely to have a psychiatric hospital admission ($OR = 13.74$, 95% C.I. 2.59 to 72.76, $p < 0.01$) in the 12-month study period than patients receiving MBT. However, after adjusting for the potentially confounding effect of differences in treatment dropout and baseline differences in age, gender, self-harm, A&E and hospital admission history, emotional dysregulation, dissociation, PTSD and substance dependence, the difference between DBT and MBT was no longer significant.

[Insert Table 2 about here].

Association between treatment type and trajectory of change in clinical outcomes over time

The unadjusted associations between treatment type and the trajectory of change in clinical outcomes over time are shown in Online Supplementary Table 1. In unadjusted models, participants receiving DBT reported a significantly steeper decline over time in incidents of self-harm ($IRR = 0.94$, 95% C.I. 0.89 to 0.99, $p < 0.01$; Figure 2) and in emotional dysregulation ($\beta = -1.42$, 95% C.I. -2.71 to -0.13, $p = 0.03$; Figure 2) than participants receiving MBT. These differences remained significant in the final models which were adjusted for treatment dropout and for other potentially confounding differences between participants (Table 3). There was no difference between participants receiving DBT or MBT in the trajectory of change in BPD severity, interpersonal relationships, or dissociation.

[Insert Table 3 about here]

[Insert Figure 2 about here].

Discussion

Summary of Findings

Patients receiving either treatment demonstrated comparable improvements in BPD severity, dissociation, and interpersonal relationships. This is compatible with meta-analyses showing that different psychotherapy models tend to achieve equivalent results,²⁷ and indeed a trial comparing the effects of DBT to another specialised model for BPD, transference-focussed psychotherapy, also found outcomes were largely equivalent.²⁸ However, despite the improvements achieved, even after completing 12 months of treatment, on average patients were still exhibiting high levels of emotional dysregulation, dissociation, and interpersonal dysfunction.

Significantly fewer participants initiating DBT- just 42% - completed 12 months of treatment. However, this difference in treatment completion rates was no longer significant after taking account of differences between participants initiating DBT and those initiating MBT, such as the higher baseline levels of emotional dysregulation and greater likelihood of recent self-harm in the DBT participants. Thus, the more severe mental health difficulties of individuals entering participating DBT programmes compared to those entering MBT programmes are likely to have contributed to the higher treatment dropout rate amongst the DBT participants. Whilst treatment completion rates were substantially higher in US trials of DBT conducted by the treatment developer (e.g. 81%, Linehan *et al.* 1991; 83%, Linehan *et al.* 2006), completion rates in US trials in routine community services tend to be lower, ranging from 76% to 48% (Landes *et al.* 2016), and other UK DBT evaluations have also found low completion rates (e.g. 36%, Zinkler *et al.* 2007; 42%, Feigenbaum *et al.* 2012; 48%, Priebe *et al.* 2012). The considerably higher treatment completion rate of 72% amongst MBT participants is consistent with the high completion in MBT trials conducted by the treatment developer (88%, Bateman & Fonagy, 1999; 73%, Bateman & Fonagy, 2009).

Despite their higher treatment dropout rate, DBT participants reported a significantly steeper decline over time in incidents of self-harm and in emotional dysregulation. This remained significant after adjusting for treatment dropout, baseline levels of self-harm and emotional dysregulation – suggesting that this difference was not just an artefact of the greater level of baseline mental health difficulties amongst DBT patients. A further difference was that just over half of DBT patients attended A&E and a quarter experienced psychiatric hospitalisation during the study year – a substantially higher rate of crisis service use than the equivalent figures of 22% and 4% in MBT patients. Similarly, 43% of DBT patients attended A&E in the treatment developer’s largest trial, and 20% experienced psychiatric hospitalisation

(Linehan *et al.*, 2006). However, DBT participants were more likely to have had high baseline levels of emotional dysregulation, a recent history of A&E, and to drop out of treatment - and after adjusting for these factors, differences in crisis service use between DBT and MBT were no longer significant. Thus, the findings do not suggest that DBT per se is less effective than MBT at reducing use of crisis services – but do highlight the more chaotic presentation of patients initiating DBT programmes than those initiating MBT programmes in our sample, and the problematic link between dropping out of treatment and poor clinical outcomes.

Implications for Research and Service Provision

Whereas DBT focusses on reducing self-harm as the primary treatment goal, and explicitly teaches emotion regulation skills (Linehan, 1993a; Linehan, 1993b), MBT aims to achieve these goals more indirectly, through the promotion of mentalizing (Bateman & Fonagy, 2006). This may explain the more rapid change in these outcomes in DBT patients. Relatedly, patients' use of the skills taught in DBT has been shown to mediate reductions in self-harming behaviour (Neacsiu *et al.* 2010, Barnicot *et al.* 2016). Could DBT's explicit focus on targeting self-harm reduction and improving emotion regulation skills render it a more rapidly acting treatment for these difficulties? A large randomised controlled trial of DBT versus MBT is required to address this question. Such a trial should also evaluate potential common and specific treatment mechanisms between the two modalities.

Given the association between treatment dropout and poor outcomes amongst people with personality disorders (McMurrin *et al.* 2010; Priebe *et al.* 2012), preventing dropout could potentially improve outcomes. Yet no research to date has evaluated methods for improving completion rates when evidence-based psychological treatments for personality disorder are

implemented in routine clinical practice. Previous research has identified that poor therapeutic alliance is one factor consistently predicting treatment dropout in patients with a personality disorder (Barnicot et al. 2011), suggesting that patients' inherent difficulties with trust and conflict resolution in attachment relationships may contribute. Another contributing factor could be that in the participating MBT services, only patients who attend the 10-week group programme, indicate their interest in further group-based treatment, and are judged by staff to have the potential to benefit from this approach are able to begin the full MBT programme. Thus, MBT patients were already selected as individuals with both the practical and emotional capability to sustain the commitment of attending treatment, whereas the DBT participants were a less selected group of individuals who may have varied more widely in their capabilities to commit. A recent audit at one of the participating MBT services found that over a 20-month period, 44 people initiated the 10-week group programme, of which 15 (34%) went on to initiate the full 18-month MBT programme. Whilst this figure does not represent dropout from the 10-week programme per se as some individuals will have completed the 10-week programme but chosen not to continue to the MBT programme, it does nonetheless suggest that incorporation of numbers discontinuing during the 10-week programme would make dropout rates from MBT more similar to those from DBT. However, individuals attending the 10-week programme did not take part in the present research project for both conceptual and practical reasons – namely, that the 10-week programme is a separate intervention in its own right and is not a part of the manualised MBT programme (Bateman & Fonagy 2006), and also that the lengthy follow-up time required to follow participants up from the point of initiating the 10-week programme was not feasible within the scope of the present project and would make comparison with a 12-month DBT programme more challenging. Future research could investigate whether a similar brief pre-DBT group programme would improve treatment completion rates amongst patients referred to DBT.

However, if only patients who successfully complete a brief pre-therapy programme are allowed to begin treatment, would this further limit patients' access to evidence-based treatments for personality disorder, which are already difficult to access in many localities and non-existent in others (Dale *et al.* 2017)? What alternative treatment will be offered to patients who lack the capacity to complete a pre-therapy programme?

Strengths and Limitations

Strengths of the present research included the high consent and follow-up rates and recruitment of participants from services implementing evidence-based treatment in a real-world setting, increasing the ecological validity of the findings. Furthermore, the use of multi-level modelling to evaluate changes over time allowed use of a relatively large amount of repeated measures data (up to $n = 395$ datapoints from 90 individuals), increasing the study's power to detect differences in outcome trajectory, and allowed the inclusion of individuals with data missing at some timepoints, which should reduce bias in the model estimates (Sterne *et al.* 2009).

The major limitation was that allocation to treatment was not randomised. While efforts were made to control for confounding, it is possible that other unmeasured differences between study groups exist and these may have been responsible for differences in clinical outcomes. It is unclear how generalisable data from this study are to services beyond those participating, and it is possible that apparent differences in outcomes between MBT and DBT are due to the organisation and delivery of treatments at these services. Borderline personality disorder is a long-term condition and it is possible that clinical outcomes of patients receiving MBT and DBT in this study diverged further or converged after completion of the 12-month follow-up. A further limitation was that it was not possible to evaluate inter-rater reliability for the SCID, MINI or SAS-II interviews. Finally, we did not assess treatment fidelity in this study

and it is possible that differences in clinical outcomes seen between these DBT and MBT services reflects differences in the quality of the treatment delivered, rather than to differences in the relative efficacy of these two treatment approaches.

Conclusion

Patients with borderline personality disorder receiving DBT or MBT in routine community services can achieve improvements in BPD traits, self-harm, emotional dysregulation, dissociation and interpersonal relationships. There may be differences in the extent and speed of reductions in self harm and emotional dysregulation among those offered DBT and MBT, but experimental studies examining treatment fidelity, mechanisms and longer-term outcomes are needed to fully examine potential differences in the clinical and cost effectiveness of these treatments.

Acknowledgments

The authors gratefully acknowledge the vital contribution of clinicians and patients from participating clinical services, and in particular thank Laura Couldrey, Jeantique Hommel and Lauren Bryan for their assistance with data processing.

Conflict of Interest

All authors declare no conflicts of interest.

Ethical Standards The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Ethical approval for the study was granted by the United Kingdom National Health Service National

Research Ethics Service Committee South East Coast – Surrey on 06/02/2014, reference number 14/LO/0158, and by the Research and Development departments of the participating NHS Trusts. All participants gave written informed consent for participation.

American Psychiatric Association (2013). *Diagnostic and statistical manual of mental disorders (5th ed.)*. American Psychiatric Association; Washington, DC.

Ansell EB, Sanislow CA, McGlashan TH, Grilo CM (2007). Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group. *Comprehensive Psychiatry* **48(4)**, 329-336.

Barnicot K, Gonzalez R, McCabe R, Priebe S (2016). Skills use and common treatment processes in dialectical behaviour therapy for borderline personality disorder. *Journal of Behaviour Therapy and Experimental Psychiatry* **52**, 147-156.

Barnicot K, Katsakou C, Marougka C, Priebe S (2011). Treatment completion in psychotherapy for borderline personality disorder: a systematic review and meta-analysis.

Acta Psychiatrica Scandinavica **123(5)**, 327-338.

Bateman A, Fonagy P (1999). The effectiveness of partial hospitalisation in the treatment of borderline personality disorder: a randomised controlled trial. *American Journal of*

Psychiatry **156**, 1563–1569.

Bateman A, Fonagy P. (2006). *Mentalization-Based Treatment for Borderline Personality Disorder: A Practical Guide*. Oxford University Press: Oxford.

Bateman A, Fonagy P (2009). Randomized controlled trial of outpatient mentalization based treatment versus structured clinical management for borderline personality disorder.

American Journal of Psychiatry **166**, 1355 – 1364.

Bernstein EM, Putnam FW (1986). Development, reliability, and validity of a dissociation scale. *Journal of Nervous and Mental Disease* **174(12)**, 727-735.

Behavioral Tech (2017). *About us: Our Impact*. Behavioral Tech: Seattle. Accessed from <https://behavioraltech.org/about-us/our-impact/> on 08-01-2018.

Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF (2007). Evaluating three treatments for borderline personality disorder: a multiwave study. *American Journal of*

Psychiatry **164**, 922–928.

Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers P (2017). Efficacy of Psychotherapies for Borderline Personality Disorder: A Systematic Review and Meta-analysis. *Journal of American Medical Association Psychiatry* **74(4)**, 319-328.

doi:10.1001/jamapsychiatry.2016.4287.

Dale O, Sethi F, Stanton C, Evans S, Barnicot K, Sedgwick R, Goldsack S, Doran M,

Shoolbred L, Samele C, Urquia N, Haigh R, Moran P (2017). Personality disorder

services in England: findings from a national survey. *British Journal of Psychiatry Bulletin* **41(5)**, 247-253. doi: 10.1192/pb.bp.116.055251.

Feigenbaum JD, Fonagy P, Pilling S, Jones A, Wildgoose A, Bebbington PE (2012). A real-world study of the effectiveness of DBT in the UK National Health Service. *British Journal of Clinical Psychology* **51**, 121–41.

First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS (1997). *Structured clinical interview for DSM-IV axis II personality disorders, (SCID-II)*. American Psychiatric Press Inc: Washington, D.C.

First MB, Spitzer RL, Miriam G, Williams JBW (2002). *Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P)*. Biometrics Research, New York State Psychiatric Institute: New York.

Gratz KL, Roemer L (2004). Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. *Journal of Psychopathology and Behavioral Assessment* 2004; **26(1)**: 41–54. DOI :10.1023/B:JOBA.0000007455.08539.94.

Herman JL, Perry JC, van der Kolk BA (1989). Childhood Trauma in Borderline Personality Disorder. *American Journal of Psychiatry* **146**, 490-495.

Landes SJ, Chalker SA, Comtois KA (2016). Predicting dropout in outpatient dialectical behaviour therapy with patients with borderline personality disorder receiving psychiatric disability. *Borderline Personality Disorder and Emotional Dysregulation* **3**, 9. DOI 10.1186/s40479-016-0043-3.

Linehan MM (1993a). *Cognitive-behavioral treatment of borderline personality disorder*. Guilford Press: New York.

Accepted version - Barnicot K, Crawford M (2019). Dialectical behaviour therapy v. mentalisation-based therapy for borderline personality disorder. *Psychological Medicine* **49**, 2060–2068. <https://doi.org/10.1017/S0033291718002878>

Linehan MM (1993b). *Skills training manual for treating borderline personality disorder*. Guilford Press: New York.

Linehan, M.M. (1996). *Instructions for use of Suicide Attempt Self- Injury Interview*. From: <http://depts.washington.edu/uwbrtc/wp-content/uploads/SASII-Instructions-For-Published-SASII.pdf>

Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL (1991). Cognitive-behavioral treatment of chronically para-suicidal borderline patients. *Archives of General Psychiatry* 48, 1060–1064.

Linehan MM, Comtois KA, Brown MZ, Heard HL, Wagner A (2006a). Suicide Attempt Self-Injury Interview (SASII): development, reliability, and validity of a scale to assess suicide attempts and intentional self-injury. *Psychological Assessment* 18(3), 303-12.

Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard H L, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N (2006b) Two-year randomized controlled trial and follow-up of dialectical behaviour therapy versus therapy by experts for suicidal behaviours and borderline personality disorder. *Archives of General Psychiatry* 63, 757- 766.

Maffei C, Fossati A, Agostoni I, Barraco A, Bagnato M, Deborah D, Namia C, Novella L, Petrachi M (1997). Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. *Journal of Personality Disorders* 11(3), 9–84.

McMurran M, Huband N, Overton E (2010). Non-completion of personality disorder treatments: A systematic review of correlates, consequences, and interventions. *Clinical Psychology Review* 30(3), 277-287.

Neacsiu AD, Rizvi SL, Linehan MM (2010). Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. *Behaviour Research and Therapy* **48**, 832-839.

Pelcovitz D, van der Kolk B, Roth S, Mandel F, Kaplan S, Resick P (1997). Development of a Criteria Set and Structured Interview for Disorders of Extreme Stress (SIDES). *Journal of Traumatic Stress* **10(1)**, 3–16. doi:10.1002/jts.2490100103.

Pfohl B, Blum N, St. John D, McCormick B, Allen J, Black DW (2009). Reliability and Validity of the Borderline Evaluation of Severity Over Time (BEST): A Self-rated Scale to Measure Severity and Change in Persons with Borderline Personality Disorder. *Journal of Personality Disorders* **23(3)**, 281-293. DOI:10.1521/pedi.2009.23.3.281.

Priebe S, Bhatti N, Barnicot K, Bremner S, Gaglia A, Katsakou C, Molosankwe I, McCrone P, Zinkler M (2012). Effectiveness and cost effectiveness of dialectical behaviour therapy for self-harming patients with personality disorder: a pragmatic randomised controlled trial. *Psychotherapy and Psychosomatics* **81**, 356-365.

Sheehan DV, Lecrubier Y, Sheehan K H, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998). The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry* **59(20)**, 22e33.

Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC (1997). The Validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. *European Psychiatry* **5**, 232-41.

Skre I, Onstad S, Torgersen S, Kringlen E (1991). High interrater reliability for the Structured Clinical Interview for DSM-III-R Axis I (SCID-I). *Acta Psychiatrica Scandinavica* **84(2)**,167-73.

StataCorp (2015). *STATA/SE, version14*. StataCorp LP.

Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR (2009). Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *British Medical Journal*, 338: b239.

Stoffers JM, Völlm BA, Rucker G, Timmer A, Huband N, Lieb K (2012). Psychological therapies for people with borderline personality disorder. *Cochrane Database of Systematic Reviews* **8**, CD005652. DOI: 10.1002/14651858.CD005652.pub2

University College London (2014). Mentalization-based therapy: improving treatment for patients with borderline personality disorders. *UCL Impact Statements: London*. Accessed from <http://www.ucl.ac.uk/impact/case-study-repository/mentalization-based-therapy-on-05--01-2018>.

Van der Kolk B (2002). *Structured Interview for Disorders of Extreme Stress Not Otherwise Specified – Self Report Version*. The Trauma Center, Justice Resource Institute: Brookline, MA.


van Ijzendoorn MH, Schuengel C (1996). The measurement of dissociation in normal and clinical populations: Meta-analytic validation of the Dissociative Experiences Scale (DES). *Clinical Psychology Review* **16(5)**, 365-382.

Wampold BE (2001). *The Great Psychotherapy Debate: Models, Methods and Findings*. Lawrence Erlbaum Associates: Mahwah, NJ.

Zanarini MC, Skodol AE, Bender D, Dolan R, Sanislow C, Schaefer E, Morey LC, Grilo CM, Shea MT, McGlashan TH, Gunderson JG (2000). The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses. *Journal of Personality Disorders* **14(4)**, 291-299.

Zinkler M, Gaglia A, Arokiadass SMR, Farhy E (2007). Dialectical behaviour treatment: implementation and outcomes. *Psychiatric Bulletin* **31**, 249–252.

Figure 1. Participant recruitment and follow-up



	Mean (s.d.) or n(%)				
	Whole Sample (N = 90)	DBT (N = 58)	MBT (N = 32)	Treatment completers (N = 48)	Treatment dropout (N = 42)
Female	65 (72%)	42 (72%)	23 (72%)	38 (81%)	26 (62%)
Male	25 (28%)	16 (28%)	9 (28%)	9 (19%)	16 (38%)*
Age (years)	31.0 (13.0)	29.3(13.5)	34.3(11.5)*	31.9 (12.0)	29.8(14.0)*

Full-time or part-time employed	22 (25%)	13 (23%)	9 (28%)	11 (24%)	11 (26%)
On sick leave	3 (3%)	3 (5%)	0 (0%)	3 (6%)	0 (0%)
Unemployed	65 (72%)	42 (72%)	23 (72%)	33 (70%)	31 (74%)
White ethnicity	58 (64%)	37 (64%)	21 (66%)	27 (58%)	30 (71%)
Black and minority ethnicity	32 (36%)	21 (36%)	11 (34%)	20 (43%)	12 (29%)
BPD Severity (BEST)	43.3 (10.3)	44.8(9.9)	40.7(10.6)	44.7(10.4)	41.4(9.8)
Emotional dysregulation (DERS)	128.7(27.3)	134.2(24.9)	120.3(29.3)**	130.9(28.3)	124.8 (25.9)
Interpersonal dysfunction (SIDES)	5.24 (2.0)	5.20 (2.0)	5.32(1.9)	5.29 (1.8)	5.17 (2.2)
Dissociation (DES)	35.3 (23.0)	36.1(22.9)	33.8(23.5)	40.3 (24.9)	28.8(18.7)**
Attended A&E in previous 12 months	45 (54%)	34 (67%)	11 (34%)***	24 (52%)	20 (56%)
Admitted to a psychiatric hospital in previous 12 months	33 (39%)	24 (46%)	9(28%)	14 (30%)	18(49%)*
Engaged in deliberate self-harm in previous 12 months	81(90%)	56 (97%)	25 (78%)**	43 (91%)	37 (88%)
Number of self-harm incidents in previous 3 months (Median (IQR)) ^a	41 (11 to 99)	42 (13 to 123)	40 (6 to 90)	40 (5 to 112)	48.5 (14.5 to 97.5)
Comorbid major depressive disorder	31 (36%)	23 (43%)	8(25%)	17 (37%)	14 (36%)
Comorbid substance dependence	23 (26%)	15 (27%)	8 (25%)	8 (17%)	15 (37%)**
Comorbid alcohol dependence	18 (20%)	14 (25%)	4 (13%)	7 (15%)	11 (27%)
Comorbid psychotic symptoms	36 (42%)	25 (46%)	11 (35%)	20 (44%)	16 (41%)
Comorbid post-traumatic stress disorder	68 (76%)	49 (85%)	19 (59%)**	36 (76%)	31 (74%)
Post-traumatic stress disorder severity ^b	35.5(8.1)	35.6(8.1)	35.3(8.4)	35.6 (8.9)	35.2 (7.2)

A&E General hospital accident and emergency department. IQR interquartile range.

^a Including only participants who had a history of self-harm in the 12 months prior to treatment (N = 81) and provided data on the number of incidents of self-harm in the prior 3 months.

^b Including only participants who met diagnostic criteria for post-traumatic stress disorder at the start of treatment (N = 68) * p < 0.10, ** p < 0.05, *** p < 0.01

Table 2. Clinical outcomes at month 12

	BPD severity (BEST) at month 12 (N = 78)	Emotional dysregulation (DERS) at month 12 (N = 75)	Alterations in relationships with others (SIDES) at month 12 (N = 68)	Dissociation (DES) at month 12 (N = 77)	Average number of incidents of self-harm in months 10 to 12 Median (IQR) (N = 68) ^a	Number of patients attending A&E between months 1 & 12 (N = 72)	Number of patients with at least 1 inpatient psychiatric admission between months 1 & 12 (N = 72)
DBT	35.0(11.5)	103.1(33.5)	5.5(3.6)	30.6(23.4)	2 (0-45)	24(51%)	12 (26%)
MBT	35.8(11.6)	108.7(29.4)	5.3(2.9)	26.6(18.9)	12.5 (0 – 90)	6 (22%) ^{*b}	1 (4%) ^{**b}

^a Includes only participants who had a history of self-harm in the 12 months prior to treatment (N = 81) and provided sufficient data at month 12 to be included in the analysis.

* p < 0.05; ** p < 0.01

^b These differences between DBT and MBT recipients were no longer significant after adjusting for treatment dropout and baseline differences in age, gender, self-harm, A&E and hospital admission history, emotional dysregulation, dissociation, PTSD and substance dependence: p > 0.05

Table 3. Adjusted associations between treatment type and trajectory of change in self-harm and emotional dysregulation

Number of incidents of self-harm: trajectory months 0, 3, 6, 9 and 12 (N = 63, n = 274) ^a			
Independent variable	Incident rate ratio	95% C.I.	p
Age	1.01	0.99 to 1.02	0.30
Female (vs. male)	1.15	0.84 to 1.58	0.39
Number of incidents of self-harm at month 0	1.01	1.01 to 1.01	<0.01
Emotional dysregulation at month 0 (DERS)	0.99	0.99 to 1.00	0.15
Dissociation at month 0 (DSS)	1.01	0.99 to 1.01	0.14
A&E admission in past 12 months	1.09	0.84 to 1.42	0.51
Psychiatric admission in past 12 months	0.84	0.64 to 1.11	0.24
Comorbid substance dependence	0.75	0.55 to 1.03	0.08
Comorbid PTSD	0.80	0.56 to 1.14	0.21
Time	0.96	0.90 to 1.03	0.29
DBT (vs. MBT)	1.12	0.75 to 1.69	0.58
DBT (vs. MBT) x Time	0.93	0.87 to 0.99	0.02
Treatment completion (vs. dropout)	0.79	0.54 to 1.17	0.24
Treatment completion x Time	0.95	0.89 to 1.01	0.08
Emotional dysregulation (DERS) trajectory months 0, 3, 6, 9 and 12 (N = 72, n = 311)			
Independent variable	β	95% C.I.	p
Age	-0.08	-0.44 to 0.28	0.66
Female (vs. male)	10.16	-0.46 to 20.78	0.06
Emotional dysregulation at month 0 (DERS)	0.35	0.08 to 0.63	0.01
Dissociation at month 0 (DSS)	0.47	0.18 to 0.77	<0.01
A&E admission in past 12 months	-4.70	-14.18 to 4.77	0.33
Psychiatric admission in past 12 months	4.22	-5.38 to 13.81	0.39
Engaged in self-harm in past 12 months	-9.81	-23.14 to 3.52	0.15
Comorbid substance dependence	-11.03	-21.20 to -0.86	0.03
Comorbid PTSD	-5.03	-17.11 to 7.05	0.41
Time	-0.42	-1.83 to 0.99	0.56
DBT (vs. MBT)	6.55	-3.78 to 16.88	0.21
DBT (vs. MBT) x Time	-1.94	-3.37 to -0.51	<0.01
Treatment completion (vs. dropout)	-8.37	-16.38 to -0.37	0.04
Treatment completion x Time	-0.96	-2.49 to 0.57	0.22

N = number of individuals with sufficient data to be included in analysis; n number of datapoints included in analysis.

^a Based on subsample of individuals who had a history of self-harm in the 12 months prior to treatment (N = 81) and provided sufficient follow-up data to be included in the analysis.


Table 4. Adjusted associations between treatment type and trajectory of change in self-harm and emotional dysregulation

Number of incidents of self-harm: trajectory months 0, 3, 6, 9 and 12 (N = 63, n = 274) ^a			
Independent variable	Incident rate ratio	95% C.I.	p
Age	1.01	0.99 to 1.02	0.30
Female (vs. male)	1.15	0.84 to 1.58	0.39
Number of incidents of self-harm at month 0	1.01	1.01 to 1.01	<0.01
Emotional dysregulation at month 0 (DERS)	0.99	0.99 to 1.00	0.15
Dissociation at month 0 (DSS)	1.01	0.99 to 1.01	0.14
A&E admission in past 12 months	1.09	0.84 to 1.42	0.51
Psychiatric admission in past 12 months	0.84	0.64 to 1.11	0.24
Comorbid substance dependence	0.75	0.55 to 1.03	0.08
Comorbid PTSD	0.80	0.56 to 1.14	0.21
Time	0.96	0.90 to 1.03	0.29
DBT (vs. MBT)	1.12	0.75 to 1.69	0.58
DBT (vs. MBT) x Time	0.93	0.87 to 0.99	0.02
Treatment completion (vs. dropout)	0.79	0.54 to 1.17	0.24
Treatment completion x Time	0.95	0.89 to 1.01	0.08
Emotional dysregulation (DERS) trajectory months 0, 3, 6, 9 and 12 (N = 72, n = 311)			
Independent variable	β	95% C.I.	p
Age	-0.08	-0.44 to 0.28	0.66
Female (vs. male)	10.16	-0.46 to 20.78	0.06
Emotional dysregulation at month 0 (DERS)	0.35	0.08 to 0.63	0.01
Dissociation at month 0 (DSS)	0.47	0.18 to 0.77	<0.01
A&E admission in past 12 months	-4.70	-14.18 to 4.77	0.33
Psychiatric admission in past 12 months	4.22	-5.38 to 13.81	0.39
Engaged in self-harm in past 12 months	-9.81	-23.14 to 3.52	0.15
Comorbid substance dependence	-11.03	-21.20 to -0.86	0.03
Comorbid PTSD	-5.03	-17.11 to 7.05	0.41
Time	-0.42	-1.83 to 0.99	0.56
DBT (vs. MBT)	6.55	-3.78 to 16.88	0.21
DBT (vs. MBT) x Time	-1.94	-3.37 to -0.51	<0.01
Treatment completion (vs. dropout)	-8.37	-16.38 to -0.37	0.04
Treatment completion x Time	-0.96	-2.49 to 0.57	0.22


N = number of individuals with sufficient data to be included in analysis; n number of datapoints included in analysis.

^a Based on subsample of individuals who had a history of self-harm in the 12 months prior to treatment (N = 81) and provided sufficient follow-up data to be included in the analysis.

Figure 2. Change in incidents of self-harm and emotional dysregulation over time



Median number of incidents of self-harm per 3 months



Mean emotional dysregulation (DERS)